← Back to home

LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA

Clinical trials for LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA trials appear

Sign up with your email to follow new studies for LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug duo aims to wipe out lingering cancer cells

Disease control Not yet recruiting

This study is testing whether two oral drugs, imlunestrant and abemaciclib, can clear tiny amounts of leftover cancer DNA from the blood in people with early-stage, hormone-sensitive breast cancer. The goal is to see if this treatment can prevent the cancer from coming back. Abou…

Matched conditions: LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA

Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA

Get alerted when new LOCALIZED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2)-NEGATIVE BREAST CARCINOMA trials appear

New drug duo aims to wipe out lingering cancer cells